CJC-1295 and ipamorelin are unapproved in Australia. What each peptide is, what the TGA has said, and what the coroner asked it to review.
Written by the Peptide Labs Research Team
CJC-1295 and ipamorelin are unapproved in Australia: the Therapeutic Goods Administration (TGA) says it has not assessed either for safety, quality or effectiveness. A Victorian coroner asked the TGA to review both on 28 October 2026.
Both are synthetic peptides studied for their link to growth hormone release, through different receptors.
| Peptide | What it is |
|---|---|
| CJC-1295 | Synthetic analogue of growth hormone-releasing hormone (GHRH) |
| Ipamorelin | Synthetic pentapeptide, a ghrelin receptor agonist |
Our research overview covers the mechanism, and the comparison with sermorelin covers the structural differences.
Neither is a TGA-approved medicine. Unapproved does not mean out of reach: the coroner's report records the TGA saying various pathways let medical practitioners access unapproved peptides. Scheduling attaches to the substance and changes over time, so check the current Poisons Standard, not a supplier's label.
The coroner asked the TGA to review the benefits and safety risks and consider further restrictions. The TGA said it is "considering whether further regulatory or other measures may be appropriate". No decision had been reported at the time of writing.
Peptide Labs supplies research peptides strictly for in-vitro laboratory use, not for human or animal use. This article reports public news and gives no use or dosing guidance.
A coroner found Richard Norton died from complications of using unapproved CJC1295 and Ipamorelin. What the finding says and how the TGA responded.
Industry & RegulationA coroner asked the TGA to review CJC1295 and Ipamorelin and consider further restrictions. What the TGA and the Medical Board have said so far.
99%+ HPLC purity · COA verified every batch · Next-day dispatch to Melbourne
Shop All Peptides